The article reports on the data published in the "U.S. Drug Approval Trends and Yearbook 2008/2009" by Parexel International Ltd. It indicates an increase in the marketing applications for new molecular entities (NMEs) which offers the best measure for true drug development outputs. It also implies that the increase in marketing applications for new active substances (NAS) signals the revival of research and drug development.